Interspecies scaling: Prediction of human biliary clearance and comparison with QSPKR

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 1, 2012, Pages 1-14

  Morris, Marilyn E ^a   Yang, Xinning ^a,c   Gandhi, Yash A ^a   Bhansali, Suraj G ^a,d   Benincosa, Lisa J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allometric scaling; Biliary clearance; Interspecies scaling; Protein binding; QSPKR

Indexed keywords

CEFALEXIN; CEFIXIME; CEFOTETAN; CEFPIRAMIDE; CEFTRIAXONE; CIPROFLOXACIN; DIBROMOSULFOPHTHALEIN; DICLOFENAC; DIGOXIN; DOXORUBICIN; ERYTHROMYCIN; INDOCYANINE GREEN; IRINOTECAN; METHOTREXATE; NAPSAGATRAN; RANITIDINE; VALSARTAN; VINCRISTINE;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE; BILE FLOW; BRAIN WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG STRUCTURE; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; EXPERIMENTAL RABBIT; HEPATOBILIARY SYSTEM; HUMAN; HUMAN EXPERIMENT; LIVER WEIGHT; NONHUMAN; QUANTITATIVE STRUCTURE PROPERTY RELATION; SPECIES COMPARISON;

ANIMALS; BILE; BILIARY TRACT; DOGS; HAPLORHINI; HUMANS; MICE; MODELS, BIOLOGICAL; PHARMACOKINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RABBITS; RATS; SPECIES SPECIFICITY;

EID: 84862783428     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1761     Document Type: Article

References (99)

1. Roberts MS, Magnusson BM, Burczynski FJ, et al. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002; 41: 751-790. (Pubitemid 34948196)
2. Demontes-Mainard F, Vincon G, Labat L, et al. Cefpiramide kinetics and plasma protein binding in cholestasis. Br J Clin Pharmacol 1994; 37: 295-297. (Pubitemid 24212191)
3. Hedman A, Angelin B, Arvidsson A, et al. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 1990; 47: 20-26. (Pubitemid 20041205)
4. Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clin Pharmacokinet 1979; 4: 368-379. (Pubitemid 10235051)
5. Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 2007; 59: 1177-1192. (Pubitemid 47615206)
6. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-227. (Pubitemid 12044187)
7. Mahmood I, Balian JD. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996; 85: 411-414. (Pubitemid 26105709)
8. Lave T, Dupin S, Schmitt C, et al. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 1997; 86: 584-590. (Pubitemid 27203406)
9. Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 2004; 32: 603-611. (Pubitemid 38668152)
10. Boxenbaum H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 1984; 9: 177-183. (Pubitemid 14077557)
11. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26: 887-895. (Pubitemid 26343083)
12. Feng MR, Lou X, Brown RR, et al. Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 2000; 17: 410-418. (Pubitemid 30395295)
13. Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 2005; 33: 1297-1303. (Pubitemid 41196972)
14. Ward KW, Azzarano LM, Bondinell WE, et al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos 1999; 27: 1232-1241.
15. Mahmood I, Sahajwalla C. Interspecies scaling of biliary excreted drugs. J Pharm Sci 2002; 91: 1908-1914. (Pubitemid 34810535)
16. Mahmood I. Interspecies scaling of biliary excreted drugs: a comparison of several methods. J Pharm Sci 2005; 94: 883-892. (Pubitemid 40577320)
17. Scatina JA, Hicks DR, Kraml M, et al. Disposition of a new tetrahydrocarbazole analgesic drug in laboratory animals and man. Xenobiotica 1989; 19: 991-1002. (Pubitemid 19230093)
18. Tanaka Y, Sekiguchi M, Sawamoto T, et al. Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. Eur J Drug Metab Pharmacokinet 1994; 19: 47-58. (Pubitemid 24203745)
19. Lave T, Portmann R, Schenker G, et al. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol 1999; 51: 85-91. (Pubitemid 29097274)
20. Yang X, Gandhi YA, Duignan DB, et al. Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure- pharmacokinetic relationships. AAPS J 2009; 11: 511-525.
21. Ng C, Xiao Y, Putnam W, et al. Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods. J Pharm Sci 2004; 93: 2535-2544. (Pubitemid 39319436)
22. Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58. (Pubitemid 27438945)
23. Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 2006; 95: 1783-1799. (Pubitemid 44229585)
24. Chiou WL, Robbie G, Chung SM, et al. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharm Res 1998; 15: 1474-1479. (Pubitemid 28427939)
25. Tang H, Hussain A, Leal M, et al. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 2007; 35: 1886-1893. (Pubitemid 47481583)
26. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284: 1677-1679. (Pubitemid 29291379)
27. Dodds PS, Rothman DH,Weitz JS. Re-examination of the '3/4-law' of metabolism. J Theor Biol 2001; 209: 9-27.
28. Millburn P. Factors in the biliary excretion of organic compounds. In Metabolic Conjugation and Metabolic Hydrolysis. Fishmen W (ed). Academic Press: New York, 1970; 1-74.
29. Tang H, Mayersohn M. A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab Dispos 2005; 33: 1294-1296. (Pubitemid 41196971)
30. Mahmood I. Prediction of human drug clearance from animal data: application of the rule of exponents and 'fu Corrected Intercept Method'(FCIM). J Pharm Sci 2006; 95: 1810-1821. (Pubitemid 44229587)
31. Mahmood I. Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J Clin Pharmacol 2000; 40: 1439-1446.
32. Mahmood I. Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metab Drug Interact 2002; 19: 49-64.
33. Mahmood I. Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species? J Pharm Sci 2009; 98: 2472-2493.
34. Matsushita H, Suzuki H, Sugiyama Y, et al. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J Pharmacobiodyn 1990; 13: 602-611. (Pubitemid 20386462)
35. Abou-El-Makarem MM, Millburn P, Smith RL, et al. Biliary excretion in foreign compounds. Species difference in biliary excretion. Biochem J 1967; 105: 1289-1293.
36. Hirom PC, Millburn P, Smith RL, et al. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 1972; 129: 1071-1077.
37. Yang X, Gandhi YA, Morris ME. Biliary excretion in dogs: evidence for a molecular weight threshold. Eur J Pharm Sci 2010; 40: 33-37.
38. Niinuma K, Kato Y, Suzuki H, et al. Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol 1999; 276: G1153-G1164. (Pubitemid 29251914)
39. Li N, Zhang Y, Hua F, et al. Absolute difference of hepatobiliary transporter multidrug resistanceassociated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos 2009; 37: 66-73.
40. Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochrome P450s and UDPglucuronosyltransferases as a novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities. Drug Metab Dispos 2011; doi:10.1124/ dmd.111.042259
41. Tucker TG, Milne AM, Fournel-Gigleux S, et al. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem Pharmacol 2011; doi:10.1016/j.bcp.2011.10. 017
42. Tang H, Mayersohn M. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 2005; 33: 1288-1293. (Pubitemid 41196970)
43. Muraoka I, Hasegawa T, Nadai M, et al. Biliary and renal excretions of cefpiramide in Eisai hyperbilirubinemic rats. Antimicrob Agents Chemother 1995; 39: 70-74.
44. Matsui H, Yano K, Okuda T. Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys. Antimicrob Agents Chemother 1982; 22: 213-217. (Pubitemid 12020109)
45. Brogard JM, Jehl F, Adloff M, et al. High hepatic excretion in humans of cefpiramide, a new cephalosporin. Antimicrob Agents Chemother 1988; 32: 1360-1364.
46. Conte JE, Jr. Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function. Antimicrob Agents Chemother 1987; 31: 1585-1588.
47. Deguchi Y, Nakashima E, Ishikawa F, et al. Peritoneal transport of beta-lactam antibiotics: effects of plasma protein binding and the interspecies relationship. J Pharm Sci 1988; 77: 559-564. (Pubitemid 19032452)
48. Komiya M, Kikuchi Y, Tachibana A, et al. Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. Antimicrob Agents Chemother 1981; 20: 176-183. (Pubitemid 11015125)
49. Lanzini A, Pigozzi MG, Wuhrer A, et al. Quantitative measurement of biliary excretion and of gall bladder concentration of drugs under physiological conditions in man. Gut 1989; 30: 104-109. (Pubitemid 19038581)
50. Martin C, Thomachot L, Albanese J. Clinical pharmacokinetics of cefotetan. Clin Pharmacokinet 1994; 26: 248-258. (Pubitemid 24116204)
51. Gill CJ, Jackson JJ, Gerckens LS, et al. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother 1998; 42: 1996-2001. (Pubitemid 28363082)
52. Merle-Melet M, Seta N, Farinotti R, et al. Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. Antimicrob Agents Chemother 1989; 33: 1506-1510. (Pubitemid 19228003)
53. Matsui H, Komiya M, Ikeda C, et al. Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys. Antimicrob Agents Chemother 1984; 26: 204-207. (Pubitemid 14050227)
54. Arvidsson A, Alvan G, Angelin B, et al. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother 1982; 10: 207-215. (Pubitemid 13253889)
55. Arvidsson A, Leijd B, Nord CE, et al. Interindividual variability in biliary excretion of ceftriaxone: effects on biliary lipid metabolism and on intestinal microflora. Eur J Clin Invest 1988; 18: 261-266.
56. Hakim L, Bourne DW, Triggs EJ. Disposition of ceftriaxone in rat: application of a pharmacokinetic- protein binding model and comparison with cefotaxime. Xenobiotica 1989; 19: 815-822. (Pubitemid 19212118)
57. Popick AC, Crouthamel WG, Bekersky I. Plasma protein binding of ceftriaxone. Xenobiotica 1987; 17: 1139-1145. (Pubitemid 17145843)
58. Mays B, Short L, Hershman MJ, et al. Relevance of protein binding to cephalosporin antimicrobial activity in vivo. Chemotherapy 1990; 36: 254-258. (Pubitemid 20251906)
59. Kitamura Y, Hirouchi M, Kusuhara H, et al. Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistanceassociated protein 3 (mrp3/abcc3). J Pharmacol Exp Ther 2008; 327: 465-473.
60. Kato S, Ito K, Kato Y, et al. Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. Pharm Res 2009; 26: 1467-1476.
61. Vlaming ML, Pala Z, van Esch A, et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 2008; 14: 8152-8160.
62. Bischoff KB, Dedrick RL, Zaharko DS, et al. Methotrexate pharmacokinetics. J Pharm Sci 1971; 60: 1128-1133.
63. Masuda M, I'Izuka Y, Yamazaki M, et al. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 1997; 57: 3506-3510.
64. Sasaki M, Suzuki H, Aoki J, et al. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 2004; 66: 450-459. (Pubitemid 39329243)
65. Ueda K, Kato Y, Komatsu K, et al. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 2001; 297: 1036-1043. (Pubitemid 32472501)
66. Nuernberg B, Koehnke R, Solsky M, et al. Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 1990; 33: 898-902. (Pubitemid 20205773)
67. Henderson ES, Adamson RH, Denham C, et al. The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys. Cancer Res 1965; 25: 1008-1017.
68. Choi YH, Bae SK, Oh JM, et al. Pharmacokinetics of intravenous methotrexate in mutant Nagase analbuminemic rats. Biopharm Drug Dispos 2007; 28: 385-392. (Pubitemid 350020229)
69. Kawahara M, SakataA, Miyashita T, et al. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci 1999; 88: 1281-1287.
70. Kawaguchi H, Matsui Y, Watanabe Y, et al. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse. J Pharmacol Exp Ther 2004; 308: 91-96. (Pubitemid 38090705)
71. Song S, Suzuki H, Kawai R, et al. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 1999; 27: 689-694. (Pubitemid 29252443)
72. Koren G, Klein J, Giesbrecht E, et al. Effects of quinidine on the renal tubular and biliary transport of digoxin: in vivo and in vitro studies in the dog. J Pharmacol Exp Ther 1988; 247: 1193-1198. (Pubitemid 19022135)
73. Hedman A, Angelin B, Arvidsson A, et al. No effect of probenecid on the renal and biliary clearances of digoxin in man. Br J Clin Pharmacol 1991; 32: 63-67.
74. Baggot JD, Davis LE. Plasma protein binding of digitoxin and digoxin in several mammalian species. Res Vet Sci 1973; 15: 81-87.
75. Hartmann G, Vassileva V, Piquette-Miller M. Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 2005; 33: 820-828. (Pubitemid 40686636)
76. Krishna R, McIntosh N, Riggs KW, et al. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res 1999; 5: 2939-2947. (Pubitemid 29493973)
77. Asakura E, Nakayama H, Sugie M, et al. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol 2004; 484: 333-339. (Pubitemid 38117227)
78. Yamaguchi S, Zhao YL, Nadai M, et al. Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 2006; 50: 80-87. (Pubitemid 43042906)
79. Speeg KV, Maldonado AL. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 1994; 34: 133-136. (Pubitemid 24157977)
80. Kiso S, Cai SH, Kitaichi K, et al. Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Anticancer Res 2000; 20: 2827-2834.
81. Suzuki T, Zhao YL, Nadai M, et al. Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistanceassociated protein (Mrp2) in rats. Life Sci 2006; 79: 455-461. (Pubitemid 43870299)
82. Maniez-Devos DM, Baurain R, Lesne M, et al. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation. J Pharmacol 1986; 17: 1-13. (Pubitemid 16042790)
83. Wilkinson PM, Israel M, Pegg WJ, et al. Comparative metabolism and excretion of adriamycin in man, monkey, and rat. Cancer Chemother Pharmacol 1979; 2: 121-125. (Pubitemid 9221323)
84. Iguchi H, ToneH, Kiyosaki T, et al. Pharmacokinetics and disposition of (2''R)-4'-O-tetrahydropyranyladriamycin in dogs. Jpn J Antibiot 1986; 39: 638-652. (Pubitemid 16050537)
85. Riggs CE Jr., Benjamin RS, Serpick AA, et al. Bilary disposition of adriamycin. Clin Pharmacol Ther 1977; 22: 234-241.
86. Jolivette LJ, Ward KW. Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. J Pharm Sci 2005; 94: 1467-1483. (Pubitemid 41168677)
87. Terasaki T, Iga T, Sugiyama Y, et al. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J Pharm Sci 1984; 73: 1359-1363. (Pubitemid 14021881)
88. Harris PA, Gross JF. Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemother Rep 1975; 59: 819-825.
89. Maniez-Devos DM, Baurain R, Trouet A, et al. Doxorubicin pharmacokinetics in the rabbit. J Pharmacol 1985; 16: 159-169. (Pubitemid 16256765)
90. Daoud SS, Huang KC. Renal handling of adriamycin. Prog Clin Biol Res 1988; 258: 161-171.
91. CamaggiCM, Comparsi R, Strocchi E, et al. Epirubicin and doxorubicin comparativemetabolismand pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 1988; 21: 221-228.
92. Powis G, Harris RN, Basseches PJ, et al. Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse. Cancer Chemother Pharmacol 1986; 16: 43-49. (Pubitemid 16186899)
93. Speeg KV, Maldonado AL, Liaci J, et al. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology 1992; 15: 899-903.
94. Thiessen JJ, Rappaport PL, Eppel JG. Indocyanine green pharmacokinetics in the rabbit. Can J Physiol Pharmacol 1984; 62: 1078-1085. (Pubitemid 14023688)
95. Chen CY, Fancher RM, Ruan Q, et al. A liquid chromatography tandem mass spectrometry method for the quantification of indocyanine green in dog plasma and bile. J Pharm Biomed Anal 2008; 47: 351-359.
96. Ketterer SG, Wiegand BD, Rapaport E. Hepatic uptake and biliary excretion of indocyanine green and its use in estimation of hepatic blood flow in dogs. Am J Physiol 1960; 199: 481-484.
97. Kawasaki S, Umekita N, Beppu T, et al. Hepatic transport of indocyanine green in dogs chronically intoxicated with dimethylnitrosamine. Toxicol Appl Pharmacol 1984; 75: 309-317. (Pubitemid 14026442)
98. Meijer DK, Weert B, Vermeer GA. Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. Eur J Clin Pharmacol 1988; 35: 295-303.
99. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095. (Pubitemid 23211439)